非小細胞肺癌市場：按類型,療法（化療,靶向療法（貝伐單抗,Necitumumab,雷莫蘆單抗）,免疫療法）,用戶,地區-規模,份額,前景,機會分析2022-2030

肺癌的症狀在早期可能不明顯，因為它們可能是其他疾病的症狀，例如肺炎或肺萎陷。肺癌的症狀包括胸痛、呼吸困難、喘息、體重減輕、持續咳嗽、聲音嘶啞或變聲、呼吸急促以及支氣管炎和肺炎等肺部問題。此外，當它通過血液和淋巴擴散到身體其他部位時，就會出現骨痛、四肢無力、皮膚發黃、眼睛發黃、頭痛和抽搐等症狀。

肺癌的診斷可能涉及診斷成像，例如 X 光、MRI、超聲和 CT，以及痰細胞學，通過吐出痰來檢查是否存在癌細胞。我有。此外，通過細針穿刺活檢、支氣管鏡、縱隔鏡等方法採集肺部異常增生和肺水腫的肺細胞，可診斷肺癌。

市場動態

在預測期內，非小細胞肺癌預計將成為市場增長的驅動力，這在很大程度上是由煙草消費增加和被動吸煙增加推動的。例如，根據2022年3月公佈的數據，美國疾病控制與預防中心（CDC）估計，每年約有4000萬美國成年人吸食香煙，估計有255萬中學生每年至少使用一支電子煙. 它聲明它使用一種煙草產品。

這項研究的主要特點

• 本報告對全球非小細胞肺癌治療市場進行了深入分析，顯示了以 2021 年為基數的預測期（2022-2030 年）的市場規模和復合年增長率 (CAGR%)年。
• 它揭示了不同細分市場的潛在收入機會，並為該市場概述了一個有吸引力的投資建議矩陣。
• 它還提供了有關市場驅動因素、制約因素、機會、新產品發布和批准、市場趨勢、區域前景以及主要參與者採用的競爭戰略的重要見解。
• 根據公司亮點、產品組合、主要亮點、財務業績和戰略等參數對全球非小細胞肺癌市場的主要參與者進行了概況分析。
• 本研究涵蓋的主要公司包括輝瑞公司、阿斯利康公司、F. Hoffmann-La Roche Ltd.、Eli Lilly and Company、Boehringer Ingelheim GMBH、Novartis AG、Bristol-Myers Squibb Company 和 Merck & Co ., 公司
• 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
• 《全球非小細胞肺癌療法市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者將能夠通過用於分析全球非小細胞肺癌市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第二章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按類型分類
  • 市場概況：按療法分類
  • 市場概況：按最終用戶分類
  • 市場概況：按地區
• 連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

• 市場動態
  • 司機
  • 約束因素
  • 市場機會
• 影響分析
• 市場趨勢
• 近期趨勢
• 收購和合作場景
• 技術概覽
• 監管情景
• 管道分析
• 害蟲分析

第 4 章全球非小細胞肺癌治療市場 - COVID-19 影響分析

• 總體影響
• 對供需的影響
• COVID-19 對市場的影響

第 5 章全球非小細胞肺癌治療市場類型，2017-2030

• 腺癌
• 鱗狀細胞癌
• 大細胞癌
• 大細胞神經內分泌腫瘤

第 6 章全球非小細胞肺癌治療市場（按療法）：2017-2030

• 化療
• 靶向治療
• 貝伐珠單抗（阿瓦斯汀）
• Necitumumab（Portorazza）
• 雷莫蘆單抗（Cyramza）
• 免疫療法
• 納武單抗 (Opdivo)
• Atezolizumab（Tecentriq）
• 其他

第 7 章全球非小細胞肺癌治療市場：按最終用戶分類，2017-2030

• 醫院
• 家庭護理
• 專科診所
• 其他

第 8 章全球非小細胞肺癌治療市場：地區，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 其他亞太地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第9章競爭格局

• Pfizer Inc.
• AstraZeneca plc
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Boehringer Ingelheim GMBH
• Novartis AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.

第 10 章

• 調查方法
• 關於出版商

Lung cancer symptoms are not noticeable in its early stage as these symptoms are considered for other type of illness such as pneumonia or collapsed lung. Some symptoms of lung cancer include chest pain, harsh/raspy sound while breathing, wheezing, weight loss, continuous cough, hoarseness or voice changes, shortness of breath, lung problems such as bronchitis or pneumonia, and others. Moreover, if it spreads through the bloodstream or the lymphatics into other parts of the body then it exhibits symptoms such as bone pain, weakness in arm or leg, yellow skin, yellow eyes, headache, and seizures.

Some diagnostic tests are performed by doctors to detect lung cancer, which include diagnostic imaging tests such as X-ray, magnetic resonance imaging (MRI), ultrasound, computed tomography scan (CT scan), and also by diagnosing mucous, which the patient can cough up to check the presence of cancer cells, which is called as sputum cytology. By taking the cells of lungs from abnormal growth area of the lung or from the fluid of lungs through the procedure called as fine needle aspiration biopsy, bronchoscopy, and mediastinoscopy, lung cancer can be diagnosed.

Market Dynamics

Increasing consumption of tobacco and active engagement in passive smoking are two major factors responsible for non-small cell lung cancer, which are expected to drive market growth over the forecast period. For instance, according to data published in March 2022, on The Centers for Disease Control and Prevention (CDC), stated that nearly 40 million U.S. adults smoke cigarettes, and an estimated 2.55 million middle and high school students use at least one tobacco product, including e-cigarettes every year.

Key features of the study:

• This report provides in-depth analysis of the global non-small cell lung cancer treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global non-small cell lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global non-small cell lung cancer treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market

Detailed Segmentation:

• Global Non-small Cell Lung Cancer Treatment Market, By Type:
  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Large Cell Neuroendocrine Tumors
• Global Non-small Cell Lung Cancer Treatment Market, By Treatment:
  • Chemotherapy
  • Targeted Therapy
    • Bevacizumab (Avastin)
    • Necitumumab (Portrazza)
    • Ramucirumab (Cyramza)
  • Immunotherapy
    • Nivolumab (Opdivo)
    • Atezolizumab (Tecentriq)
  • Others
• Global Non-small Cell Lung Cancer Treatment Market, By End User:
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
• Global Non-small Cell Lung Cancer Treatment Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Pfizer Inc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca plc
  • Hoffmann-La Roche Ltd.
  • Eli Lilly and Company,
  • Boehringer Ingelheim GMBH
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Treatment
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pipeline Analysis
• PEST Analysis

4. Global Non-small Cell Lung Cancer Treatment Market- COVID-19 Impact Analysis

• Overall Impact
• Impact on Supply and Demand
• COVID-19 Impact on the market

5. Global Non-small Cell Lung Cancer Treatment Market, By Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Adenocarcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Squamous Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Large Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Large Cell Neuroendocrine Tumors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Non-small Cell Lung Cancer Treatment Market, By Treatment, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Chemotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Targeted Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Bevacizumab (Avastin)
• Necitumumab (Portrazza)
• Ramucirumab (Cyramza)
• Immunotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Nivolumab (Opdivo)
• Atezolizumab (Tecentriq)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Non-small Cell Lung Cancer Treatment Market, By End User, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Homecare
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Specialty Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Non-small Cell Lung Cancer Treatment Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AstraZeneca plc
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche Ltd.
  • Company Highlights
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Boehringer Ingelheim GMBH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us